Research concludes professional disease education leads to greater treatment adoptions.
Through its Veeva Pulse Field Trends Report, Veeva Systems has announced the findings of field medical's impact on clinical practice. According to the report’s analysis, disease state education by medical science liaisons (MSLs) with key opinion leaders (KOLs) before launch leads to 1.5 times greater treatment adoption.
Reportedly, scientific engagement with KOLs provides an enduring impact on new treatment adoption. Despite this discovery, 70% only engage with one company's field medical team, leaving a need for better field planning and connected insights across organizations.
"The right data is foundational to our engagement strategy. We can quickly identify who the relevant KOLs are and organize those KOLs based on when and where they are sharing scientific information and what scientific information they are sharing," said Christine Castro, director of medical affairs excellence, Lundbeck, in a company press release. "As we prepared for the launch of new treatments, this data-driven approach helped us build the right relationships and focus our resources where they will have the greatest scientific impact."
Reference: Veeva Pulse Uncovers Field Medical Engagement Drives 1.5x Increase in Treatment Adoption. PR Newswire. July 26, 2023. Accessed July 28, 2023. https://www.prnewswire.com/news-releases/veeva-pulse-uncovers-field-medical-engagement-drives-1-5x-increase-in-treatment-adoption-301885869.html
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
FDA Approves Samsung Bioepis Biosimilars Ospomyv and Xbryk
February 18th 2025Ospomyv, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Xbryk, a biosimilar to Xgeva, is indicated for preventing skeletal-related events in multiple myeloma and solid tumor bone metastases.